Method for constructing carrier containing klenow-fragment reverse complementary sequences
A reverse complementary, large fragment technology, applied in the field of molecular biology, can solve the problems of time-consuming and laborious, no positive clone growth, low success rate, etc., and achieve the effect of strong operability, great application value and short time.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0038] This embodiment provides a method for constructing a vector containing a large fragment reverse complementary sequence, comprising the following steps:
[0039] 1. Segmentation containing large fragments of reverse complementary sequences: as attached Figures 1A-1B As shown, the fragment (target fragment 1: SEQ ID NO.1) that needs to be constructed in this embodiment contains a 516bp reverse complementary sequence ( Figure 1A The two underlined parts in the middle, the part in bold font in the middle is a non-complementary sequence, and the length of each underlined part is 516bp). First we split the sequence into two fragments (F1-1 (SEQ ID NO.2) and F1-2 (SEQ ID NO.3) without reverse complementary sequences, Figure 1B The sequence between the underlined part is the target sequence). These two fragments were synthesized separately in a gene synthesis company in Suzhou, and BsaI restriction sites were added to both ends of the fragments (attached Figures 1A-1B , ...
Embodiment 2
[0057] This embodiment provides a method comprising a large fragment reverse complementary sequence vector, comprising the following steps:
[0058] 1. Segmentation containing large fragments of reverse complementary sequences: as attached Figure 4A and 4B As shown, the fragment to be constructed (target fragment 2: SEQ ID NO.5) contains a 609bp reverse complementary sequence. First we split the sequence into two fragments without reverse complement (F2-1: SEQ ID NO.6 and F2-2: SEQ ID NO.7, see Figure 4B , wherein F2-1 includes a structure without a complementary sequence, and the F2-2 sequence has a corresponding complementary sequence in F2-1). These two fragments were synthesized separately in a gene synthesis company in Suzhou, and BmsBI restriction sites were added to both ends of the fragments ( Figure 4B ) contains the target fragment 2 of the reverse complementary sequence of the large fragment. Divide the target sequence into two segments, and add BmsBI restric...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


